Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3,3’-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression

Arijit Bhowmik; Sayak Chakravarti; Aparajita Ghosh; Rajni Shaw; Suman Bhandary; Satyaranjan Bhattacharyya; Parimal C. Sen; Mrinal K. Ghosh

doi:10.18632/oncotarget.18689

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3,3’-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression

Arijit Bhowmik, Sayak Chakravarti, Aparajita Ghosh, Rajni Shaw, Suman Bhandary, Satyaranjan Bhattacharyya, Parimal C. Sen and Mrinal K. Ghosh _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:65339-65358. https://doi.org/10.18632/oncotarget.18689

Metrics: PDF 2048 views | HTML 3722 views | ?

Abstract

Arijit Bhowmik1, Sayak Chakravarti1,*, Aparajita Ghosh2,*, Rajni Shaw1,*, Suman Bhandary2, Satyaranjan Bhattacharyya3, Parimal C. Sen2 and Mrinal K. Ghosh1

1Signal Transduction in Cancer and Stem Cells Laboratory, Translational Research Unit of Excellence (TRUE), Division of Cancer Biology and Inflammatory Disorder, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), Kolkata 700091, India

2Division of Molecular Medicine, Bose Institute, Centenary Campus, Kolkata 700054, India

3Division of Surface Physics, Saha Institute of Nuclear Physics, Kolkata 700064, India

*These authors have contributed equally to this work

Correspondence to:

Mrinal K. Ghosh, email: [email protected]

Keywords: glioma, blood brain barrier, 3,3’-diindolylmethane encapsulated nanoparticle, somatostatin receptor 2 peptide, epidermal growth factor receptor

Received: November 22, 2016 Accepted: May 22, 2017 Published: June 27, 2017

ABSTRACT

Current therapy for Glioblastoma is insufficient because of the presence of blood brain barrier. It limits the transport of essential drugs to the tumor sites. To overcome this limitation we strategized the delivery of an anticancer compound 3,3’-diindolylmethane by encapsulation in poly (lactic-co-glycolic acid) nanoparticles. These nanoparticles were tagged with a novel peptide against somatostatin receptor 2 (SSTR2), a potential target in glioma. The nanoformulation (27-87nm) had loading and encapsulation efficiency of 7.2% and 70% respectively. It was successfully internalized inside the glioma cells resulting in apoptosis. Furthermore, an in vivo bio-distribution study revealed the selective accumulation of the nanoformulation into rat brain tumor sites by crossing the blood brain barrier. This resulted in abrogation of epidermal growth factor receptor pathway activation in glioma cells. Our novel nanopreparation therefore shows great promise to serve as a template for targeted delivery of other therapeutics in treating GBM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18689

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3,3’-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression

Abstract